Aug 8 (Reuters) - Mesoblast Ltd
- Phase 2 trial of mesoblast cell therapy shows dose-related clinical benefit in patients with biologic refractory rheumatoid arthritis
- Intends to enter into a strategic partnership to advance phase 3 development of allogeneic mpcs for biologic refractory ra
- A single intravenous infusion of proprietary allogeneic mpc product candidate, mpc-300-iv, was well tolerated
(([email protected];))
News: MSB Mesoblast intends to enter into strategic partnership advancing phase 3 development of...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |